Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Business Wire•23/10/2026•13:37 ET
2
Key Highlights
- ➤Sefaxersen cut proteinuria 43.1% versus placebo at 37 weeks, P<0.0001
- ➤Phase 3 IMAgINATION enrolled 459 adults with primary IgA nephropathy
- ➤Hematuria resolution was greater with sefaxersen among patients with baseline hematuria
- ➤Sefaxersen was well tolerated with no new safety signals
- ➤Roche will share data with health authorities seeking treatment approval
Expert Statements
Brett P. Monia, Chief executive officer of Ionis Pharmaceuticals
“These data support our belief that sefaxersen is uniquely positioned to treat IgA nephropathy, demonstrating significant and clinically meaningful reduction in proteinuria and offering the potential to help reduce the need for long-term dialysis or kidney transplantation”
Brett P. Monia, Chief executive officer of Ionis Pharmaceuticals
“Sefaxersen is a powerful example of the broad impact of Ionis' innovative science, and based on these results, we believe it has the potential to be an important new treatment option for people living with IgA nephropathy.”
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
– Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups –
Get started
Create a free account to read the full story.